CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2018—Kite Pharma announced that the FDA has approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.
Read More »